PLUS THERAPEUTICS INC

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

CNSY$0.68+19.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Deficit

(In thousands, except share data)

Convertible · Additional · Total
Preferred stock · preferred stock · Common stock · Treasury Stock · paid-in · Accumulated · stockholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · (deficit)/equity
Balance at December 31, 2022	—	$	—	1,952	$	—	2,240,092	$	2	—	$	—	$	473,628	$	(467,185)	$	6,445
Stock-based compensation	—		—	—		—	—		—	—		—		140		—		140
Sale of common stock, net	—		—	—		—	168,164		—	—		—		895		—		895
Issuance of Series F preferred stock	1		—	—		—	—		—	—		—		1		—		1
Net loss	—		—	—		—	—		—	—		—		—		(4,805)		(4,805)
Balance at March 31, 2023	1	$	—	1,952	$	—	2,408,256	$	2	—	$	—	$	474,664	$	(471,990)	$	2,676
Redemption of Series F preferred stock	(1)		—	—		—	—		—	—		—		—		—		—
Fractional adjustment	—		—	—		—	(1,310)		—	—		—		—		—		—
Sale of common stock, net	—		—	—		—	472,674		1	—		—		1,327		—		1,328
Share-based compensation	—		—	—		—	—		—	—		—		140		—		140
Net loss	—		—	—		—	—		—	—		—		—		(1,482)		(1,482)
Balance at June 30, 2023	—		—	1,952	$	—	2,879,620	$	3	—	$	—	$	476,131	$	(473,472)	$	2,662
Sale of common stock, net	—		—	—		—	1,589,655		2	—		—		2,954		—		2,956
Issuance of common stock for in process research and development	—		—	—		—	53,381		—	—		—		75		—		75
Stock-based compensation	—		—	—		—	—		—	—		—		148		—		148
Net loss	—		—	—		—	—		—	—		—		—		(3,219)		(3,219)
Balance at September 30, 2023	—		—	1,952	$	—	4,522,656	$	6	—	$	—	$	479,308		(476,691)	$	2,622
Balance at December 31, 2023	—	$	—	1,952	$	—	4,522,656	$	5	(78,559)	$	(126)	$	479,274	$	(480,501)	$	(1,348)
Stock-based compensation	—		—	—		—	—		—	—		—		146		—		146
Purchase of treasury stock	—		—	—		—	—		—	(179,866)		(374)		—		—		(374)
Net loss	—		—	—		—	—		—	—		—		—		(3,261)		(3,261)
Balance at March 31, 2024	—	$	—	1,952	$	—	4,522,656	$	5	(258,425)	$	(500)	$	479,420	$	(483,762)	$	(4,837)
Issuance of common stock	—		—	—		—	1,439,988		1	—		—		—		—		1
Stock-based compensation	—		—	—		—	—		—	—		—		151		—		151
Net loss	—		—	—		—	—		—	—		—		—		(2,940)		(2,940)
Balance at June 30, 2024	—	$	—	1,952	$	—	5,962,644	$	6	(258,425)	$	(500)	$	479,571	$	(486,702)	$	(7,625)
Reclass of warrants to equity	—		—	—		—	—		—	—		—		5,200		—		5,200
Stock-based compensation	—		—	—		—	—		—	—		—		125		—		125
Exercise of pre-funded warrants	—		—	—		—	192,114		—	—		—		—		—		—
Net loss	—		—	—		—	—		—	—		—		—		(2,874)		(2,874)
Balance at September 30, 2024	—	$	—	1,952	$	—	6,154,758	$	6	(258,425)	$	(500)	$	484,896	$	(489,576)	$	(5,174)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.